49 results on '"Eclache, Virginie"'
Search Results
2. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53
3. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
4. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia
5. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
6. Intérêt de la cytogénétique et de la biologie moléculaire pour le diagnostic des syndromes lymphoprolifératifs B
7. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia
8. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?
9. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience
10. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases
11. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
12. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogénétique Hématologique study
13. Detection of chromosomal abnormalities associated with chronic lymphocytic leukemia: what is the best method?
14. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy
15. Clinical and biological features associated with taste loss in internal medicine patients. A cross-sectional study of 100 cases
16. M0 AML, clinical and biologic features of the disease, includingAML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH)
17. CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique
18. Détection du chromosome Philadelphie chez les patients atteints de leucémie myéloïde chronique: Places respectives de la cytogénétique de l'hybridation in situ en fluorescence et de l'analyse moléculaire par RT-PCR
19. Characterisation of a New Clinical Presentation of Chronic Lymphocytic Leukemia with Symptomatic Nasopharyngeal Mucosa Involvement
20. Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement
21. The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants
22. A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)
23. TP53, XPO1 and ATM Mutations Exclusive Distribution in the Adverse Prognosis Chronic Lymphocytic Leukemia (CLL) Group
24. High Frequency of Mutations in BTK and PLCG2 in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Therapy
25. A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group
26. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters
27. Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases
28. Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?
29. MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM
30. Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder
31. Therapeutic Strategies in Patients with Atypical CML (aCML) and Unclassified MDS/MPN (MDS/MPN-U). a Single Center Report
32. Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS)
33. A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation
34. Association Of More Than One B Cell Clone Arises In Any Type Of Leukemic Chronic B Cell Disorder
35. Old DAT / New Data : Positive Direct Antiglobulin Test Identifies a Specific Subgroup Of CLL Patients
36. NOTCH1 Mutations Are Associated With The 14q Deletion In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
37. Cryptic deletion involving the ATM locus at 11q22.3∼q23.1 in B-cell chronic lymphocytic leukemia and related disorders
38. 2.55 CLL Cell Survival Depends on B Cell Receptor Signaling-Induced NFAT2 Activation
39. A constitutional translocation t(1;4)(p21;p15) in a case of chronic lymphocytic leukemia
40. Treatment of Lower Risk MDS with Del 5q by Lenalidomide, with or without G-CSF: Current Results of the French Patient Named Program (ATU)
41. Loss of the Y Chromosome in Philadelphia-Positive Cells Predicts a Poor Response of CML Patients to Imatinib Mesylate Therapy.
42. Deletions of Chromosomes 6q and 13q, and Trisomy 4 Are the Most Common Cytogenetic Abnormalities in Waldenstrom Macroglobulinemia. Preliminary Results of a Multicentric Study.
43. Characteristics and Outcome of MDS with Isolated Del 20q: The GFM Experience in 64 Cases.
44. Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.
45. Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)
46. Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.
47. Prognostic Impact of Cytogenetic Abnormalities in Elderly Patients with Acute Myeloid Leukemia (AML) Enrolled in the ALFA-9803 Trial.
48. Correlations between BCR-ABL Ratio and Cytogenetic Response at Months 12 of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.
49. Analysis of B-CLL with Discordant ZAP-70 Expression and IgVH Mutational Status.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.